New Blood Test Technology May Impact GIST Treatment
A new blood test technology may lead to major changes in treatment of Gastrointestinal Stromal Tumors. Keep reading for more information.
Research Team Meets in New Jersey
The LRG research team meets four times a year, with at least one in-person meeting per year. This year, the team held its in-person meeting at the LRG office in New Jersey March 22-24, 2013.
First report of a GIST patient responding to a BRAF inhibitor
First report of a GIST patient responding to a BRAF inhibitor. Dr. Gerald Falchook and colleagues at MD Anderson Cancer Center provided the first report of a GIST patient responding to a BRAF inhibitor. The BRAF gene is frequently mutated in melanoma and BRAF inhibitors provide one of the most important therapies available for melanoma patients
The LRG Pushes for New Ways to Research Rare Disease
Communication is a two-way street, but unfortunately that is not always the case when finding ways to research rare disease. Sharing of data by researchers does not happen as easily, or as often as you [...]
Antibody Slows GIST Growth According to Stanford University Study
A recent study at Stanford University School of Medicine shows that an antibody slows GIST growth. The study shows that the antibody binds itself to the surface of a GIST Tumor and causes the growth of cancer cells to slow in the mice they tested.
GIST Tumors – Surgery May Improve Survival Rate For Imatinib Patients
Resecting GIST tumors may improve survival rates. Surgically removing residual gastrointestinal stromal tumors in patients who respond to imatinib therapy
LRG Research Team holds quarterly meeting
The LRG Research Team recently held a teleconference that focused primarily on a study the team will collaborate on and intends to publish.
LRG Research Team members publish results of imatinib combination study
Drs. Jonathan Fletcher, of Brigham & Women’s Hospital, Harvard University and Maria Debiec-Rychter, of the Catholic University in Leuven, Belgium, members of the LRG Research Team were part of a recently published study that looked at the effectiveness of GDC-0941, a PI3K inhibitor when used in combination with imatinib (Gleevec).
2013 GI ASCO GIST summary
This is a brief summary of abstracts presented at the 2013 GI ASCO meeting. Please note that abstracts have not been through a complete peer review process and are considered to be preliminary.
Understanding How GISTs Develop Enables Discovery of New Therapies
By Drs. Sebastian Bauer, West German Cancer Center, University of Essen, Germany and Jonathan Fletcher, Brigham & Women’s Hospital, Harvard University, LRG Research Team Researchers talk plainly about microGISTs, how this cancer develops and what all [...]